The future of weight-loss drugs is uncertain, especially amid a surge in complaints about severe health issues, prompting a legal review of these claims. Over 70 lawsuits have been filed in federal courts against Novo Nordisk and Eli Lilly, the makers of Ozempic and Mounjaro, after several patients reported vision loss from using these medications, according to a EuroNews report. Serious Health Issues The lawsuits allege that GLP-1 agonists, used for weight loss and diabetes treatment, have caused nonarteritic anterior ischemic optic neuropathy (NAION), a condition where blood flow to the optic nerve is blocked, leading to vision loss. Other lawsuits claim that GLP-1 agonists can cause gastroparesis, a condition that slows down the digestive process. Legal Action A federal judicial panel has approved consolidating the cases for review by a federal judge in Pennsylvania. Earlier, U.S. President Donald Trump announced that drugmakers Eli Lilly, which produces Zepbound, and Novo Nordisk, which produces Ozempic, Rybelsus, and Wegovy, would lower the cost of popular medications for diabetes and weight loss.
